Bob Radie, president and chief executive officer of Egalet Corporation in Wayne, will be a presenter at the 13th annual Needham Healthcare Conference on Wednesday, April 9, at the Westin, N.Y. Grand Central Hotel.

The 2:20 p.m. presentation will be audio webcast live and also available for replay at Egalet’s website, http://egalet.investorroom.com/eventsandwebcasts.

In other news, the specialty pharmaceutical company announced it was added to the Russell 3000®, Russell 2000® and Russell Global Indexes as part of Russell Investments’ first quarter IPO additions. The change to the indexes took effect March 31.

The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000®, representing approximately 10 percent of the total market capitalization of that index. Membership in the Russell 2000® Index includes automatic inclusion in the appropriate growth and style indexes. Russell Investments determines membership for its equity indexes primarily by objective market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies and approximately $4.1 trillion in assets are benchmarked to Russell Indexes.

Egalet Corporation is a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products to treat pain. Egalet has created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient.

Its lead product candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development to treat moderate to severe chronic pain. There are currently no commercially available abuse-deterrent formulations of morphine, and if approved, Egalet believes that Egalet-001 would fill a significant unmet need in the marketplace.

Its second product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe chronic pain. The Egalet technology can be applied broadly across different classes of pharmaceutical products.